EBS Q1 2023 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$164M-46.6% YoY

Gross Profit

-$24M-14.8% margin

Operating Income

-$148M-89.8% margin

Net Income

-$186M-113.3% margin

EPS (Diluted)

$-3.65

QoQ Revenue Growth

-50.2%

Cash Flow

Operating Cash Flow

-$184M

Free Cash Flow

-$199M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.7B

Stockholders' Equity

$1.2B

Cash & Equivalents

$430M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$308M	-46.6%
Gross Profit	-$24M	$106M	-123.0%
Operating Income	-$148M	$6M	-2406.3%
Net Income	-$186M	-$4M	-4932.4%

Revenue Segments

Product

$143M87%

Contract Development And Manufacturing

$15M9%

Contracts and Grants

$7M4%

Geographic Segments

Services Segment

$15M100%